Downloaded from
Limitations of Antinuclear Antibody Tests (HEp-2) Are Overcome with the Autoimmune Target Test (IT-1) in Systemic Lupus Erythematosus
To the Editor:Controversy concerning the antinuclear antibody (ANA)-positive rates in patients with systemic lupus erythematous (SLE) has persisted, and many efforts in improving the test quality have been made. After reading the article "Abnormal ANA titers are less common than generally assumed in established cases of SLE" by Sjöwall, et al 1 , we would like to express our opinion. In this article, the 95th percentile titer (women 1:200, men 1:80) of healthy blood donors was chosen as the standard in determining the cutoff titer for the ANA test in patients with SLE. As a result, the article reported a fluorescent ANA-positive rate in patients with established SLE as 76%, and it focused on its result of a lower positive rate. However, this finding may result in misunderstanding, by leading investigators to accept a much lower ANA-positive rate than what had been previously reported. Further, it has a potential threat in questioning the basic pathogenesis of SLE, which is destined to possess ANA. Looking at the data from this article, the positive rates were low even when the cutoff titers were similar to the conventional screening titers (84% in 1:50, 80% in 1:100), and the positive rate in healthy blood donors at 1:40 dilution level was as high as 45%. Looking at all these aspects, it would be more reasonable to think that the problem lies with the limitation of the HEp-2 cell line in detecting autoantibody in patients with established SLE than to merely conclude that abnormal ANA titers are less common. These limitations have been recognized in many studies testing the HEp-2 cell line. It would also be hard to deny that such limitations have troubled many investigators in interpreting their data.To overcome such limitations of the HEp-2 cell line, a human macrophage cell line, IT-1, was introduced along with HEp-2000 at the 1994 American College of Rheumatology conference 2,3 . It is currently commercialized and has passed Korea Food and Drug Administration inspection as the autoimmune target (AIT) test. This test is currently used in Korea and it is included as part of the quality control program supervised by the Korean Society for Laboratory Medicine 4 . In 2 trials of ANA tests using the IT-1 cell line, on 208 SLE patients in 1999 and on 588 patients in 2007, all were reported to be positive 5,6 . Also, the ANA test results we obtained from 234 healthy blood donors showed only an 8.5% positive result, which was markedly lower than the result reported using the HEp-2 cell line. Further, the positive rate was even lower, at 5.1%, when new autoantibodies that were not reported with the use of the HEp-2 cell line were excluded 7,8 , showing results near the 95th percentile at 1:40 screening titer (Table 1). For cases of antibody against SSA/Ro antigen, suspected as a main cause of ANA-negative lupus, all showed positive results in 67 patients who were confirmed...